“I-MOVE” towards monitoring seasonal and pandemic influenza vaccine effectiveness: lessons learnt from a pilot multi-centric case-control study in Europe, 2008-9

Eurosurveillance - Tập 14 Số 44 - 2009
Esther Kissling1, Marta Valenciano1, José Marinho Falcão2, Amparo Larrauri3, Katarina Widgren4,5, Daniela Piţigoi6, Beatrix Oroszi7, Baltazar Nunes2, Camelia Savulescu4,3, A Mazick5, Emilia Lupulescu6, B C Ciancio8, Alain Moren1
1Epiconcept, Paris, France
2Instituto Nacional de Saude Dr Ricardo Jorge, Lisbon, Portugal
3Instituto de Salud Carlos III, Madrid, Spain
4European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, Stockholm, Sweden
5Statens Serum Institute, Copenhagen, Denmark
6Cantacuzino Institute, National Institute of Research – Development for Microbiology and Immunology, Bucharest, Romania
7National Center for Epidemiology, Budapest, Hungary
8European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

Tóm tắt

Within I-MOVE (European programme to monitor seasonal and pandemic influenza vaccine effectiveness (IVE)) five countries conducted IVE pilot case-control studies in 2008-9. One hundred and sixty sentinel general practitioners (GP) swabbed all elderly consulting for influenza-like illness (ILI). Influenza confirmed cases were compared to influenza negative controls. We conducted a pooled analysis to obtain a summary IVE in the age group of ≥65 years. We measured IVE in each study and assessed heterogeneity between studies qualitatively and using the I2 index. We used a one-stage pooled model with study as a fixed effect. We adjusted estimates for age-group, sex, chronic diseases, smoking, functional status, previous influenza vaccinations and previous hospitalisations. The pooled analysis included 138 cases and 189 test-negative controls. There was no statistical heterogeneity (I2=0) between studies but ILI case definition, previous hospitalisations and functional status were slightly different. The adjusted IVE was 59.1% (95% CI: 15.3-80.3%). IVE was 65.4% (95% CI: 15.6-85.8%) in the 65-74, 59.6% (95% CI: -72.6 -90.6%) in the age group of ≥75 and 56.4% (95% CI: -0.2-81.3%) for A(H3). Pooled analysis is feasible among European studies. The variables definitions need further standardisation. Larger sample sizes are needed to achieve greater precision for subgroup analysis. For 2009-10, I-MOVE will extend the study to obtain early IVE estimates in groups targeted for pandemic H1N1 influenza vaccination.

Từ khóa


Tài liệu tham khảo

Thông tin
Thông tin xuất bản

Eurosurveillance

Tập 14 Số 44

Thông tin tác giả